Table 1.
Main clinical and metabolic data in the study population according to the presence of prediabetes.
| Control Group (n = 5457) |
Prediabetes (n = 2731) |
p-Value | |
|---|---|---|---|
| Women, n (%) | 2616 (47.9) | 1551 (56.8) | <0.001 |
| Age (years) | 56 (52–62) | 59 (54–64) | <0.001 |
| Caucasian, n (%) | 5440 (99.7) | 2712 (99.3) | 0.013 |
| HbA1c (%) | 5.4 (5.2–5.5) | 5.8 (5.7–6.0) | <0.001 |
| Obesity, n (%) | 1580 (29.0) | 1094 (40.1) | <0.001 |
| Blood hypertension, n (%) | 2015 (36.9) | 1290 (47.2) | <0.001 |
| Systolic BP (mm Hg) | 129 (119–141) | 132 (121–143) | <0.001 |
| Diastolic BP (mm Hg) | 81 (75–88) | 82 (75–88) | 0.184 |
| Antihypertensive drugs, n (%) | 1569 (28.8) | 1103 (40.4) | <0.001 |
| Dyslipidemia, n (%) | 2798 (51.3) | 1622 (59.4) | <0.001 |
| Total cholesterol (mg/dL) | 202 (179–229) | 206 (183–232) | <0.001 |
| Lipid-lowering agents, n (%) | 831 (15.2) | 646 (23.7) | <0.001 |
| Antithrombotic drugs, n (%) | 141 (2.6) | 106 (3.9) | 0.001 |
Data are expressed as a median [interquartile range] or n (percentage). HbA1c: glycated hemoglobin; BP: blood pressure. Obesity was defined as a body mass index ≥30 kg/m2. Antihypertensive drugs include angiotensin-converting enzyme (ACE) inhibitors, diuretics, angiotensin-II receptor antagonists (ARA II), beta-blockers, calcium antagonists, and other antihypertensives. Lipid-lowering treatments involve statins, fibrates, ezetimibe, and omega-3 fatty acids. Antithrombotic drugs include anticoagulants and antiplatelets.